PRESS RELEASE
Ho Chi Minh City, February 20, 2024
IMEXPHARM INAUGURATES REPRESENTATIVE OFFICE IN HO CHI MINH CITY, ENHANCING BRAND PRESENCE AND SERVICE TO CUSTOMERS, PARTNERS, AND INVESTORS DAY BY DAY.
Today, Imexpharm Pharmaceutical Joint Stock Company officially inaugurated its representative office in Ho Chi Minh City. This is a significant milestone marking a positive transformation of Imexpharm in its operations as well as increasing the presence and brand recognition in major cities to better serve and care for customers, partners, and investors.
Imexpharm's leadership conducting ribbon-cutting ceremony for the office inauguration
Located on the 24th floor of Flemington Tower (Gia Bao Building) at 184 Le Dai Hanh Street, District 11, Imexpharm's representative office spans 600m2 and is designed with an open, modern, and luxurious concept. Dominated by the brand's primary blue color, the office is equipped with modern IT systems, highly interactive workspaces to create a dynamic working environment and foster cohesion among employees. Additionally, the reception area is designed to provide a friendly atmosphere for customers, partners, and investors.
Dr. Tran Thi Dao, General Director of Imexpharm Pharmaceutical Joint Stock Company, speaking at the inauguration ceremony of the representative office in Ho Chi Minh City.
Speaking at the inauguration ceremony of the representative office in Ho Chi Minh City, Dr. Tran Thi Dao, General Director and People's Pharmacist, said: "As a company with a history of over 45 years in Dong Thap Province, Imexpharm is proud to have become a leading pharmaceutical manufacturer in Vietnam. With our development strategy and expansion of the network, Imexpharm officially inaugurates an office in Ho Chi Minh City to increase brand presence in major cities and better serve customers, partners, and investors."
"In the coming time, Imexpharm will expand its network to the Northern region to provide high-quality healthcare products at reasonable prices to hospitals, pharmacies, and the general public. Not only meeting the healthcare needs domestically, Imexpharm also aims to penetrate other potential markets. As of January 2024, we have successfully exported the first batch of antibiotics to Mongolia by air freight," added Dr. Tran Thi Dao.
Imexpharm employees working at the new representative office
To date, Imexpharm has built an extensive network across the North, Central, and South regions with 20 sales branches, 2 Branch Offices in Ho Chi Minh City, and 2 warehouses in Ho Chi Minh City and Dong Thap Province. Currently, Imexpharm operates 4 manufacturing clusters, including 3 EU-GMP-standard clusters with 11 production lines meeting EU-GMP standards.
By the end of 2023, Imexpharm continued to maintain double-digit growth in 2023 with a total gross revenue of 2,113 billion VND, a 26% growth compared to the market average growth of 8%. Net revenue reached 1,994 billion VND, a 21% growth compared to the same period. Currently, Imexpharm ranks first in antibiotics in the Vietnamese market (including both foreign and domestic companies). In 2023, Imexpharm registered an additional 11 EU MAs (Marketing Authorizations) granted for 6 products, including difficult products such as Ampicillin/Sulbactam, bringing the total number of EU MAs to 27 for 11 products.
In 2024, Imexpharm will continue to invest and implement initiatives to increase productivity of existing production lines and factories. Additionally, the Company is also researching and evaluating the feasibility of new factory and production line investment projects to further meet domestic and international demand.
About Imexpharm:
Established in 1977 in Dong Thap Province, Vietnam, Imexpharm has always prioritized quality as its top priority to provide high-quality, safe, and effective healthcare products for patients and the community.
To date, Imexpharm owns four manufacturing clusters, including three EU-GMP-standard clusters with 11 production lines meeting EU-GMP standards. This has made Imexpharm the pharmaceutical manufacturing enterprise with the largest EU-GMP-standard manufacturing cluster and the most EU-GMP-standard production lines to date. Currently, Imexpharm is a manufacturing partner of many leading multinational pharmaceutical corporations such as Sandoz, DP Pharma, Galien, Pharmacience Canada, Sanofi – Aventis. As of the end of 2022, Imexpharm has obtained 12 registrations for 7 products in Europe.
For more information, please visit:
https://imexpharm.com/